Intelia Therapeutics, Inc. (NTLA) reported $ 0.57 earnings per share for the quarter, beating the Zacks ’consensus estimate of $ 4 0.54, which you can check at https://www.webull.com/quote/nasdaq-ntla. This compares with a loss of $ 0.43 per share a year ago. These figures are adjusted for items that are not repeated.

This quarterly report stands at -5.56% earnings surprise. A quarter ago, the company was expected to post a loss of $ 0.61 per share, which actually generated a loss of $ 49 0.49, giving it a surprise of 19.67%.

Over the past four quarters, the company has exceeded consensus EPS estimates three times.

Intelia Therapeutics, Inc. It is also part of Jax Medical – Biomedical and Genetics, which reported revenue of $ 10.94 million for the quarter ended December 2019, which surpassed the Zacks consensus estimate of 14.56%. This compares with year-on-year revenue of 88 7.88 million. The company has topped three times in the past four quarters in consensus earnings estimates.

Intelia Therapeutics, Inc.

Intelia Therapeutics, Inc. While the market has not performed well this year, the question that comes to mind of investors is: What’s next for the stock?

There are no easy answers to this important question, but a reliable measure to help investors overcome this is the company’s earnings vision. Not only does this include current consensus earnings expectations for the upcoming quarter (s), but also how these expectations have changed recently.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings valuation corrections. Investors can monitor such amendments themselves or rely on a tried and tested valuation tool such as Zacks Rank, which has an impressive track record of using the power of earnings valuation corrections.

Prior to this earnings release, valuation revisions for Intelia Therapeutics, Inc. were mixed. The volume and direction of valuation revisions may change following the company’s now-published earnings report, which translates into Zacks Rank # 3 (BD) for the current position stock. Therefore, the shares are expected to adapt to the market in the future. Here’s a complete list of today’s Zacks # 1 Ranked (Strong Buy) stocks.

It will be interesting to see how estimates for the coming quarters and changes for the current fiscal year change. Current consensus EPS estimate – 46 0.46 for the current quarter and $ 2.38 for the current fiscal year of $ 43.89 million.

Investors should note that the industry outlook can also have a material impact on the performance of the stock. According to the Jacks industry rankings, medical – biomedical and genetics currently rank in the top 37% of the 250 plus jacks industries. Our research shows that the top 50% of jackass-ranked businesses outnumber the bottom 50% by a factor of 2 to 1. If you want to know more stock news like Nasdap fnsr, you can check at https://www.webull.com/quote/nasdaq-fnsr.